Eli Lilly’s ‘game-changing’ diabetes drug could boost the stock, SVB Securities says

Eli Lilly ‘s new diabetes drug, which may also address obesity in patients, could lead to even more gains for the company’s stock, according to SVB Securities. Analyst David Risinger initiated coverage of Eli Lilly with an outperform rating, saying in a Sunday note that investors are failing to price in the potential of tirzepatide, or Mounjaro, as treatments for diabetes and obesity. Mounjaro was recently approved by the Food and Drug Administration to treat Type 2 diabetes, and is being investigated for potential use for obesity. “We believe that consensus underappreciates the sales potential for Lilly’s recently-approved tirzepatide (brand name Mounjaro) for diabetes and obesity, and we expect upward estimate revisions to drive stock outperformance,” Risinger wrote. SVB Securities also issued a $341 price target, representing nearly 14% upside from Friday’s closing price. Shares of Eli Lilly have outperformed this year, up 8% year to date while the S & P 500 is down 18% over the same time period. However, analysts believe they have further to go, especially if tirzepatide is covered by employers for weight loss. “Employers historically hesitated to cover obesity drugs because they view them as aesthetic agents which did not yield meaningful health benefits,” Risinger wrote. “But what is game-changing about tirzepatide is its ability to transform overall patient health by driving such significant weight loss.” SVB analysts are also bullish on the company’s drug pipeline beyond tirzepatide. The company has more treatments addressing diabetes and obesity, as well as cardiovascular disease, the note said. Notably, they’re more skeptical on the company’s treatment for Alzheimer’s. “We are recommending LLY shares despite the stock’s high valuation because we believe the company’s ability to transform the treatment of obesity is underappreciated, and even if Alzheimer’s news flow is negative, we see meaningful positive optionality in other pipeline candidates,” the note read. Shares of Eli Lilly popped 1% in Monday premarket trading. —CNBC’s Michael Bloom contributed to this report.

The Eli Lilly logo is shown on one of the company’s offices in San Diego, California, September 17, 2020.

Mike Blake | Reuters

Eli Lilly’s new diabetes drug, which may also address obesity in patients, could lead to even more gains for the company’s stock, according to SVB Securities.

Source

Business

Rivian’s AI, autonomy impress Wall Street, but EV and capital concerns remain

December 12, 2025

Rivian CEO RJ Scaringe at the company’s first “Autonomy and AI Day” on Dec. 11, 2025, in Palo Alto, California. Lora Kolodny | CNBC Rivian Automotive impressed Wall Street on Thursday with its plans for artificial intelligence, automation and an internally developed silicon chip, but significant challenges involving demand and capital remain for the electric […]

Business

Homeowners are losing thousands in equity thanks to weakening prices

December 12, 2025

A tract of new tightly packed homes are viewed along the Boulder City Parkway on January 11, 2022 in Henderson, Nevada. George Rose | Getty Images Home values have been losing ground for much of this year, with previously huge annual gains shrinking to nothing. The result is that homeowners are losing equity. Borrower equity […]

AI shopping could drive 3 billion in holiday sales. Walmart and Target are racing to get in

Business

AI shopping could drive $263 billion in holiday sales. Walmart and Target are racing to get in

December 12, 2025

Holiday shopping has always felt like a “chore” for Amrita Bhasin. Between deciding what to buy, comparing prices and checking reviews, the 24-year-old retail tech CEO said she spent more than 15 hours each year buying gifts for her friends and family, a process that took the joy out of giving. But this year, Bhasin […]